NeurimmiRs: MicroRNAs in the neuroimmune interface

Hermona Soreq; Yochai Wolf

doi:10.1016/j.molmed.2011.06.009

NeurimmiRs: MicroRNAs in the neuroimmune interface

Hermona Soreq^*
, Yochai Wolf

^*Corresponding author for this work

Alexander Silberman Institute of Life Sciences

Research output: Contribution to journal › Review article › peer-review

179 Scopus citations

Abstract

Recent reports of microRNA (miR) modulators of both neuronal and immune processes (here termed NeurimmiRs) predict therapeutic potential for manipulating NeurimmiR levels in diseases affecting both the immune system and higher brain functions, such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS) and anxiety-related disorders. In our opinion, NeurimmiRs that function within both the nervous and the immune systems, such as miR-132 and miR-124, may act as 'negotiators' between these two interacting compartments. We suggest that NeurimmiRs primarily target transcriptional or other regulatory genes, which enables modulation of both immune and cognitive processes through direct or indirect alterations of neuron-glia and/or brain-to-body signaling. Thus, manipulating NeurimmiR control over the immune contributions to cognitive pathways may offer new therapeutic targets.

Original language	English
Pages (from-to)	548-555
Number of pages	8
Journal	Trends in Molecular Medicine
Volume	17
Issue number	10
DOIs	https://doi.org/10.1016/j.molmed.2011.06.009
State	Published - Oct 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.molmed.2011.06.009

Cite this

@article{5db2091a054542f3b371723ac438dc21,

title = "NeurimmiRs: MicroRNAs in the neuroimmune interface",

abstract = "Recent reports of microRNA (miR) modulators of both neuronal and immune processes (here termed NeurimmiRs) predict therapeutic potential for manipulating NeurimmiR levels in diseases affecting both the immune system and higher brain functions, such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS) and anxiety-related disorders. In our opinion, NeurimmiRs that function within both the nervous and the immune systems, such as miR-132 and miR-124, may act as 'negotiators' between these two interacting compartments. We suggest that NeurimmiRs primarily target transcriptional or other regulatory genes, which enables modulation of both immune and cognitive processes through direct or indirect alterations of neuron-glia and/or brain-to-body signaling. Thus, manipulating NeurimmiR control over the immune contributions to cognitive pathways may offer new therapeutic targets.",

author = "Hermona Soreq and Yochai Wolf",

year = "2011",

month = oct,

doi = "10.1016/j.molmed.2011.06.009",

language = "אנגלית",

volume = "17",

pages = "548--555",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Ltd.",

number = "10",

}

TY - JOUR

T1 - NeurimmiRs

T2 - MicroRNAs in the neuroimmune interface

AU - Soreq, Hermona

AU - Wolf, Yochai

PY - 2011/10

Y1 - 2011/10

N2 - Recent reports of microRNA (miR) modulators of both neuronal and immune processes (here termed NeurimmiRs) predict therapeutic potential for manipulating NeurimmiR levels in diseases affecting both the immune system and higher brain functions, such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS) and anxiety-related disorders. In our opinion, NeurimmiRs that function within both the nervous and the immune systems, such as miR-132 and miR-124, may act as 'negotiators' between these two interacting compartments. We suggest that NeurimmiRs primarily target transcriptional or other regulatory genes, which enables modulation of both immune and cognitive processes through direct or indirect alterations of neuron-glia and/or brain-to-body signaling. Thus, manipulating NeurimmiR control over the immune contributions to cognitive pathways may offer new therapeutic targets.

AB - Recent reports of microRNA (miR) modulators of both neuronal and immune processes (here termed NeurimmiRs) predict therapeutic potential for manipulating NeurimmiR levels in diseases affecting both the immune system and higher brain functions, such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS) and anxiety-related disorders. In our opinion, NeurimmiRs that function within both the nervous and the immune systems, such as miR-132 and miR-124, may act as 'negotiators' between these two interacting compartments. We suggest that NeurimmiRs primarily target transcriptional or other regulatory genes, which enables modulation of both immune and cognitive processes through direct or indirect alterations of neuron-glia and/or brain-to-body signaling. Thus, manipulating NeurimmiR control over the immune contributions to cognitive pathways may offer new therapeutic targets.

UR - https://www.scopus.com/pages/publications/80053563273

U2 - 10.1016/j.molmed.2011.06.009

DO - 10.1016/j.molmed.2011.06.009

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 21813326

AN - SCOPUS:80053563273

SN - 1471-4914

VL - 17

SP - 548

EP - 555

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

IS - 10

ER -

NeurimmiRs: MicroRNAs in the neuroimmune interface

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this